期刊
CURRENT OPINION IN CELL BIOLOGY
卷 42, 期 -, 页码 121-127出版社
CURRENT BIOLOGY LTD
DOI: 10.1016/j.ceb.2016.07.008
关键词
-
类别
资金
- Medical Research Council [MR/K501372/1]
- Cancer Research UK [C8218/A18673]
- MRC [G0901609] Funding Source: UKRI
- Cancer Research UK [12007, 18673] Funding Source: researchfish
- Medical Research Council [1365527, G0901609] Funding Source: researchfish
- Worldwide Cancer Research [12-1068] Funding Source: researchfish
Angiogenesis, the formation of new blood vessels from preexisting ones, is thought to enhance tumour growth and these blood vessels can act as conduits of tumour cell metastasis. Integrins, the family of cell surface extracellular matrix receptors, can promote endothelial cell migration and survival, both essential features of angiogenesis, and were thus considered good targets for anti-angiogenic therapy. This sparked the development of agents to block integrin function as new cancer therapies. Here, we review the current status of alpha v beta 3-integrin in tumour angiogenesis. Learning from what we now know about integrin conformational changes and endocytosis, we discuss the possible future of targeting blood vessel avb3-integrin in the control of cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据